For example, FUS–BBBD itself has been shown to reduce the accumulation of amyloid β (Aβ) and hyperphosphorylated tau, which are thought to be pathogenic in Alzheimer’s disease, without the administration of exogenous therapeutics in the Alzheimer’s disease model (Jordao et al., 2013; Burgess et al., 2014; Leinenga and Götz, 2015; Karakatsani et al., 2019; Pandit et al., 2019). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.